التفاصيل البيبلوغرافية
| العنوان: |
二甲双胍与2型糖尿病患者帕金森病发病 风险的关联：基于宁波市鄞州区数据的 回顾性队列研究 (Chinese) |
| العنوان البديل: |
Association between metformin and the risk of Parkinson′s disease in patients with type 2 diabetes: a retrospective cohort study based on data from Yinzhou District, Ningbo City. (English) |
| المؤلفون: |
柴三葆, 赵厚宇, 孙烨祥, 沈鹏, 林鸿波, 詹思延, 孙凤 |
| المصدر: |
Chinese Journal of Diabetes Mellitus; Oct2023, Vol. 15 Issue 10, p963-971, 9p |
| الملخص (بالإنجليزية): |
Objective To explore the association between metformin use and the risk of Parkinson′s disease (PD) in patients with type 2 diabetes mellitus (T2DM) in Yinzhou District, Ningbo City. Methods This was a retrospective cohort study and T2DM patients were recruited from the Yinzhou Regional Health Care Database as research subjects. This study adopted an active drug control and new drug user design, with sulfonylurea drugs as the control, in which a cohort of new users of metformin or sulfonylureas after January 1, 2009 was assembled. Inverse probability of treatment weighting (IPTW) was used to control for the baseline confounding factors, and the Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of the association between Met use and incidence of PD. Results A total of 79 111 patients with T2DM were included. The cohort included 41 116 new users of metformin and 37 995 new users of sulfonylureas. During the follow-up period, there were 799 incident cases of PD occurred, 471 were in the sulfonylurea group and 328 were in the metformin group. The incidence rates were 186.7 per 100 000 person-years (471/252 326)and 147.7 per 100 000 person-years (328/222 011), respectively. Compared with sulfonylureas, the crude analysis without adjusting any confounding showed that there was a significant negative association between the use of metformin and the incidence of PD, with an HR of 0.80 (95%CI 0.70-0.93). After adjusting for potential confounders with IPTW, metformin was not significantly associated with the risk of PD (HR=0.88, 95%CI 0.76-1.01). The results of the subgroup and sensitivity analyses were generally consistent with those of the primary analysis. Conclusion There is no significant association between the use of metformin and the risk of PD in T2DM patients in Yinzhou District, Ningbo City. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
目的 探讨宁波市鄞州区2型糖尿病（T2DM）患者使用二甲双胍（Met）与帕金森病（PD） 发病风险的关联。方法 回顾性队列研究, 选取宁波市鄞州区医疗数据平台中的T2DM患者作为研 究对象。采用活性药物对照、新用药者设计, 以磺脲类药物（SU）作为对照, 构建2009年1月1日后新 使用Met或SU的T2DM患者队列。使用逆治疗概率加权（IPTW）来控制基线的混杂因素, 并使用Cox 回归模型估计Met与PD发病风险之间关联的HR值及其95%CI。结果 共纳入79 111例T2DM患者。 其中, Met新使用者41 116例, SU新使用者37 995例。随访期间有799例患者发生PD, 其中471例为 SU 使用者, 328 例为Met 使用者, 发病率分别为186.7/10 万人年（471/252 326）和147.7/10 万人年 （328/222 011）。与SU相比, 不调整混杂的粗分析结果显示, Met与PD的发病率之间存在显著的负相 关（HR=0.80, 95%CI 0.70~0.93）。使用IPTW校正潜在混杂因素后, Met与PD的发病风险关联无统计 学意义（HR=0.88, 95%CI 0.76~1.01）。不同亚组分析和敏感性分析的结果与主分析的结果基本一致。 结论 宁波市鄞州区T2DM患者使用Met与PD的发病风险无显著相关性。. [ABSTRACT FROM AUTHOR] |
|
Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
